Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device

Slaven Pikija1, Georg Pilz1, Gerald Gschwandtner2, Cornelia Rösler1, Konstantin Schlick3, Richard Greil3 and Johann Sellner1,4*

1 Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University Salzburg, Salzburg, Austria,
2 Department of Geriatric Medicine, Christian Doppler Medical Center, Paracelsus Medical University Salzburg, Salzburg, Austria,
3 Laboratory of Immunological Molecular Cancer Research, Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria, 4 Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München, Germany

Acute central nervous system (CNS) toxicity and immune-related side effects are increasingly recognized with the use of monoclonal antibodies for cancer therapy. Here, we report a patient who developed acute-onset encephalopathy and coma, which began shortly after administration of panitumumab for the treatment of metastatic colorectal cancer. Echocardiography revealed that the drug had been infused into the left cardiac ventricle via a dislocated central venous line. Diffusion-weighted magnetic resonance imaging disclosed multiple cortical hyperintensities, which were preferentially located in the frontal lobes. While the neurological condition improved within a few days, the patient died 4 weeks later. It seems likely that the administration of the antibody via the intra-arterial route contributed to the development of this condition. Toxic encephalopathy may be a hitherto unrecognized complication of panitumumab treatment and should be taken into consideration in patients developing CNS symptoms undergoing this therapy.

Keywords: panitumumab, immune-mediated, encephalopathy, accidental arterial infusion, cancer

INTRODUCTION

Colorectal cancer is the second leading cause of cancer mortality in the developed world and third most common cancer worldwide (1). Epidermal growth factor receptor (EGFR) is a key therapeutic target, given that its activation stimulates key signaling processes involved in tumor growth and progression. Monoclonal antibodies against EGFR including cetuximab (Erbitux®, Merck, KGaA, Darmstadt, Germany) and panitumumab (Vectibix®, Amgen Inc., Thousand Oaks, CA, USA) have emerged to an important component in the treatment regimen for metastatic colorectal cancer. Considerable improvements in both progression-free survival and overall survival were achieved with the introduction of these therapies to 5-fluorouracil (5-FU)-based chemotherapy either in combination with oxaliplatin or irinotecan (2, 3). Panitumumab, a fully human monoclonal
IgG2 antibody specific to the extracellular domain of EGFR, is approved for the treatment of EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) V-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) (2). In Europe, panitumumab is indicated for metastatic colorectal cancer in the first-line setting with FOLFOX (5-FU, leucovorin, and oxaliplatin) as well as second line with FOLFIRI (5-FU, leucovorin, and irinotecan) following first-line fluoropyrimidine regimens that did not contain irinotecan (4).

The overall rate of severe adverse events (Grade 3 and more) with panitumumab is low. However, mild to moderate toxicities are common and include skin rash, diarrhea, and hypomagnesemia (4, 5). Side effects related to the central nervous system (CNS) beyond headache and dizziness, however, have not been reported with panitumumab so far. Accidental intra-arterial injection of substances due to incorrect central venous catheter location is rare. Commonly, injury distal to the injection site occurs, and multiple processes are believed to be involved in the pathogenesis of tissue damage (6). Here, we report a patient who developed acute encephalopathy and coma after accidental infusion of panitumumab into the left cardiac ventricle via a dislocated central venous line (Port-a-Cath®).

CASE REPORT

A 48-year-old woman was diagnosed with weakly differentiated (both KRAS and NRAS Exon 2/3/4 wild-type) rectosigmoidal cancer (cTx cN1 cM1 with disseminated pulmonal and hepatic metastases) in March 2016. She had received her first course of palliative FOLFOX chemotherapy consisting of folinic acid (200 mg/m²), 5-fluourouracil (200 mg/m² as bolus and 400 mg/kg through a pump over 22 h), and oxaliplatin (85 mg/m² over 2 h) plus panitumumab (6 mg/kg over 60 min). A central line (Port-a-Cath®) was implanted 1 week prior to the first cycle, and all treatments were well tolerated at this time.

Her heart examination was unremarkable when she had an ischemic stroke 11 months earlier caused by spontaneous right internal carotid artery dissection. Back then, acute management included intravenous recombinant tissue-plasminogen activator (rt-PA), mechanical thrombectomy, and carotid artery stenting.

Three weeks later, she was admitted for the second chemotherapy cycle. The infusion line was flushed with sodium chloride solution before panitumumab administration (diluted in 100 ml sodium chloride). Shortly after completion of the panitumumab infusion using an infusion pump and a 0.2-μm in-line filter via the indwelling central venous catheter, she developed flexion of both arms and tremor in all extremities, and subsequent loss of consciousness. Upon neurologic examination she was comatose, had roving eyes, and bilateral Babinski signs. EEG did not show epileptiform activity. Brain MRI performed 5 h from symptom onset revealed multiple cortical hyperintensities on diffusion-weighted imaging (DWI). These were located in both hemispheres and preferentially in the frontal lobes (Figures 1A–C). No occlusion of major intracranial vessels was detected on time-of-flight angiography.

Pathological values in the lab exams included CRP 9.51 mg/dl (0.00–0.50), LDH 494 U/l (135–225), CK 531 U/l (26–140), cholesterol 477 mg/dl (150–220), LDL 398 mg/dl (50–150), serum iron 20 μg/dl (37–145), ferritin 178 ng/ml (23–110), and

![FIGURE 1 | MRI images of brain.](image-url)
Panitumumab-Associated Encephalopathy – A Case Report

Pikija et al.

Diseases of the CNS are a frequent complication of cancer therapies, especially if patients received chemotherapy or biologics. In the presented case, a 51-year-old female patient developed encephalopathy directly after the start of panitumumab therapy as part of her treatment of a breast cancer relapse, leading to a 50% reduction of the primary tumor. A massive venous thrombosis with a dislocation of the catheter and subsequent embolism to the brain, as no thrombotic material was detected in heart ultrasound and upon evacuation of the catheter. Increased CRP may raise suspicion for septic embolism caused by vegetation. However, blood cultures were negative for bacterial growth, and CSF examination revealed only high lactate. Together with increased NSE serum levels, this finding was consistent with brain injury. With regard to cerebral infarction, it is very unlikely that thrombi, which detach from DVT and relocate via the PFO, can cause such widespread cortical lesions. DVT may be a consequence of cancer per se or consequence of hyperviscosity, as discussed later. Pulmonary hypertension caused by embolism may have supported dislocation of the device. Thus, central venous devices in patients with DVT should undergo verification of its location. In addition, regular heart ultrasound for reconfirmation of correct placement may reduce the chance of dislocation and accidental administration of substances.

Acute neurovascular toxicity and posterior reversible encephalopathy syndrome (PRES) are the most probable underlying causes of brain injury in our patient. Panitumumab binds with high affinity to the extracellular domain of EGFR in both tumor and normal tissue cells. While many neurons of the CNS constitutively express the EGFR, glial and endothelial cells demonstrate induced receptor expression following acute injury or chronic neurodegeneration. Toxic encephalopathy is supported by the presumed panitumumab concentration in the cerebrovascular system after intracardiac administration, whereas a diluting effect can be assumed when infused via the venous route. Indeed, there are several mechanisms of action identified by in vitro studies, which could induce vascular dysfunction and subsequent brain damage. These include (1) downregulation of EGFR through receptor internalization, (2) induction of apoptosis via inhibition of EGFR signaling pathways, (3) induction of cell cycle arrest, (4) induction of autophagy, and (5) inhibition of angiogenesis. No information is available on the ability of panitumumab to cross blood–brain barrier, whereas intracranially grown GBM xenografts responded to systemically administered cetuximab treatments. An occlusion of microvessels due to undiluted protein particles needs to be taken into account as panitumumab can form protein particles. The usage of a protein filter should eliminate this option. Microvascular thrombosis may also be caused by increased viscosity, as seen occasionally with intravenous immunoglobulin (IVIG). A majority of strokes caused by IVIG treatment occur during or within 24 h of the infusion. In the case of encephalopathy caused by tocilizumab, a monoclonal antibody against interleukin-6-receptor, brain biopsy revealed multifocal cerebral thrombotic microangiopathy. The quick resolution of symptoms as well as lack of further immune-mediated complications and multi-organ involvement renders the latter condition unlikely.

Another option for the symptoms displayed by this patient is PRES. Of note, PRES is increasingly recognized as a complication of patients with cancer. In an US American cohort, more than half of the patients (55%) had received chemotherapy or targeted therapy within the months before PRES developed. This clinico-radiological entity is characterized by acute encephalopathy, seizures, and additional neurologic symptoms and neuroimaging, demonstrating lesions with posterior and
white matter predominance. This contrasts our case where EEG was normal and brain lesions were mostly frontal and cortical. PRES has been reported with bevacizumab, a humanized antibody that targets vascular endothelial growth factor (VEGF), with a minimum incidence of 0.01% (16, 18). Moreover, PRES as well as seizures have been observed with systemic cetuximab therapy (19, 20). So far, no cases of panitumumab-associated PRES are known, and our patient was normotensive. Notably, a retrospective study of 96 patients with PRES revealed that those who received recent chemotherapy or immunosuppressive medications had significantly lower mean arterial pressure than those with PRES of other etiologies (21). Electrolyte disorders and particularly hypomagnesemia is a common side effect of panitumumab treatment (22). While hypomagnesemia can cause CNS dysfunction per se, it may also be relevant for the pathogenesis of PRES (23). While magnesium levels were normal in our patient, serum levels are not a reliable means to determine total magnesium depletion (24).

Despite the fact that the clinical symptoms developed in close relation to the antibody infusion and prior to the second FOLFOX cycle, we cannot rule out the impact of comorbidity and previous medication including chemotherapy. We conclude that acute encephalopathy may be a hitherto unrecognized complication of treatment with panitumumab and should be taken into consideration in patients developing CNS symptoms undergoing this therapy. Direct interaction of the antibody with neuronal structures or indirect pathomechanisms could be envisioned. Cerebral ischemia caused by paradoxical embolism, hyperviscosity, or other mechanism of action, however, cannot be completely ruled out.

**AUTHOR CONTRIBUTIONS**

SP: drafting/revising the manuscript, accepts responsibility for conduct of research and final approval; GP, GG, CR, KS, and RG: revising manuscript and acquisition of data, accepts responsibility for conduct of research and final approval; JS: drafting/revising the manuscript, acquisition of data, and accepts responsibility for conduct of research and final approval.

**ACKNOWLEDGMENTS**

The authors would like to thank Prof. Eugen Trinka for continuous support.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fneur.2016.00196/full#supplementary-material.

**VIDEO S1|** The transthoracal heart ultrasound during the bubble test detects the distal part of the misplaced central venous access device and air bubbles in left ventricle. The catheter is floating in the LA, and the tip is protruding through mitral valve into the LV with numerous gaseous bubbles originating from it. Duration: 30 s. Abbreviations: RA, right atrium; LA, left atrium; LV, left ventricle.

**REFERENCES**

1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut (2016). doi:10.1136/gutjnl-2015-310912
2. Douillard JY, Siena S, Cassidy J, Tabernero J, BurkeS, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol (2010) 28:4697–705. doi:10.1200/JCO.2009.27.4860
3. Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Mesetaetrical colorectal cancer: a systematic review of the value of current therapies. Clin Colorectal Cancer (2016) 15:1–6. doi:10.1016/j.clcrc.2015.10.002
4. Furlor J. Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther (2012) 5:133–42. doi:10.2147/OTT.S134112
5. Berger MD, Lenz HI. The safety of monoclonal antibodies for treatment of colorectal cancer. Expert Opin Drug Saf (2016) 15:799–808. doi:10.1517/14740338.2016.1167186
6. Sen S, Chini EN, Brown MJ. Complications after unintentional intra-arterial injection of drugs: risks, outcomes, and management strategies. Mayo Clin Proc (2005) 80(6):783–95. doi:10.4065/51025–6196(2011)61533–4
7. Garajova I, Nepoti G, Paragona M, Brandi G, Biasco G. Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation. Eur J Cancer Care (Engl) (2013) 22:125–32. doi:10.1111/13.b.12008
8. Ahn D, Brickner ME, Dowell J. Embolic stroke secondary to an indwelling catheter in a patient with a patent foramen ovale: a case report and review of the literature. Clin Adv Hematol Oncol (2012) 10:335–7.
9. Daniel ES, Dean AE, Lim M, Master M, Gibbs P, Faragher I. Incidence of pulmonary embolism in patients with newly diagnosed colorectal cancer. ANZ J Surg. doi:10.1111/ans.13789
10. Siddiqui S, Fang M, Ni B, Lu D, Martin B, Maudsley S. Central role of the EGF receptor in neurometabolic aging. Int J Endocrinol (2012) 2012:739428. doi:10.1155/2012/739428
11. Lo L, Patel D, Townsend AR, Price TJ, Pharmacoxygenic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol (2015) 11:1907–24. doi:10.1517/17452555.2015.112787
12. Pillay V, Alaff A, Wilding AL, Donohue J, Court NW, Greenall SA, et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia (2009) 11:448–58, 442 p following 458. doi:10.1593/neo.090230
13. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IV Ig. Neurology (2003) 60:1822–4. doi:10.1212/01.WNL.0000068335.01620.9D
14. Jewell P, Anoroge K, Luker W, Irani SR, Zamboni G. Tocilizumab-associated multifocal cerebral thrombotic microangiopathy. Neurol Clin Pract (2016) 6:224–6. doi:10.1212/CNP.0000000000000220
15. Le EM, Loghin ME. Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients. Curr Oncol Rep (2014) 16:383. doi:10.1007/s11912-014-0383-3
16. Singer S, Grommes C, Reiner AS, Rosenblum MK, Deangelis LM. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist (2015) 20:806–11. doi:10.1634/theoncologist.2014-0149
17. Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummla S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single-institution retrospective study. J Neurooncol (2016) 128:75–84. doi:10.1007/s11060-016-2078-0
18. Porcello Marrone LC, Marrone BF, Pascoal TA, Schilling LP, Soder RB, Ferreira SS, et al. Posterior reversible encephalopathy syndrome associated with aortic arch surgery: a single-institution experience. J Neurooncol (2015) 124:275–83. doi:10.1007/s11060-015-1750-7
with FOLFOX chemotherapy. Case Rep Oncol Med (2013) 2013:306983. doi:10.1155/2013/306983

19. Palma JA, Gomez-Ibanez A, Martin B, Urrestarazu E, Gil-Bazo I, Pastor MA. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab. Neurologist (2011) 17:273–5. doi:10.1097/NRL.0b013e3182173655

20. McClellan NH, Bell WA. Seizure activity during cetuximab infusion in a patient with metastatic colorectal cancer. Am J Health Syst Pharm (2012) 69:1881–4. doi:10.2146/ajhp110637

21. Liman TG, Böhner G, Heuschmann PU, Endres M, Siebert E. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol (2012) 259:155–64. doi:10.1007/s00415-011-6152-4

22. Wang Q, Qi Y, Zhang D, Gong C, Yao A, Xiao Y, et al. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol (2015) 36:3471–82. doi:10.1007/s13277-014-2983-9

23. Chardain A, Mesnage V, Alamowitch S, Bourdain F, Crozier S, Lenglet T, et al. Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: a frequent association? Rev Neurol (Paris) (2016) 172:384–8. doi:10.1016/j.neurol.2016.06.004

24. Espay AJ. Neurologic complications of electrolyte disturbances and acid-base balance. Handb Clin Neurol (2014) 119:363–82. doi:10.1016/B978-0-7020-4086-3.00023-0

Conflict of Interest Statement: RG reported receiving honoraria from Bristol-Myers-Squibb, Cephalon, Amgen, Eisai, Mundipharma, Merck, Janssen-Cilag, Genentech, Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Roche, and Sanofi-Aventis; research funding from Cephalon, Celgene, Amgen, Mundipharma, Genentech, Pfizer, GSK, and Ratiopharm. Also, RG has been a consultant for Bristol-Myers-Squibb, Cephalon, and Celgene. The other authors declare that they have no competing interests.

Copyright © 2016 Pikija, Pilz, Gschwandtner, Rösler, Schlick, Greil and Sellner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.